The US Court of Appeals for the Federal Circuit remanded the case to the Patent Trial and Appeal Board to consider patent validity.
The agreement will enable Beijing-based RocGene to distribute its qPCR systems, reagents, and consumables in South Korea and to explore additional market strategies.
The firm's CEO expects lab capital expenditures to return to normal by the second half of 2026 as the overall life science ...
The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.
The analyzer is designed to provide extended differential and rapid C-reactive protein whole blood measurement.
The agency cleared lab-based and point-of-care infectious disease and clinical chemistry tests as well as software for digital pathology.
The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.
The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.
The company said that preliminary Q4 revenue was up 39 percent year over year and full-year 2025 revenue increased 35 percent ...
The firm's benchtop TruVerus system can now run a total of 26 FDA-cleared assays in three modalities from a single blood collection tube.
The autoimmune diagnostic company expects its new assay to be available by the end of this year or in early 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results